Tag: CEPI
Serum Institute of India joins CEPI global network to boost production...
Capability expansion will support rapid development of outbreak vaccines for use in Global South countries when faced with a future ‘Disease X’
BioAsia 2023: India’s ingenuity has been in releasing vaccines at large...
Dr Richard Hatchett, CEO, CEPI, UK in his plenary talk at the 20th edition of BioAsia
India developed four indigenous vaccines in just two years: Dr Jitendra...
DBT through “Mission COVID Suraksha”, delivered four vaccines, augmented the manufacturing of Covaxin
India will make significant investment in vaccine R&D, assures govt
While efforts are still on to uncover findings about the COVID-19 and the epidemiological models, India is ready to invest in future challenges
CEPI and SK bioscience partner to advance mRNA vaccine technology
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
Universal COVID-19 vaccine can be game-changer for developing countries like India,...
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine
CEPI commits US$4.8 million to Intravacc for developing intranasal Betacoronavirus vaccine
Under the terms of the funding agreement, Intravacc has committed to achieving equitable access to the outputs of this project, in line with CEPI’s Equitable Access Policy
Variant-Proof SARS-CoV-2 Vaccine: a CEPI-funded ExcellGene partnership with Bharat Biotech &...
An entirely new “chimeric” spike antigen complex, different from any protein of existing SARS-CoV-2 variants, will be generated
CEPI partners with Japan’s NEC Group to develop AI-designed broadly protective...
If this innovative approach is proven to be successful, it may also be applicable for developing vaccines against other pathogens in the CEPI portfolio
IVI & Bharat Biotech begin Chikungunya vaccine trials in Costa Rica
Phase II and III trials are funded by the Coalition for Epidemic Preparedness Innovations (CEPI) with support from the Ind-CEPI mission of the Department of Biotechnology (DBT), India.............................